Targeting MiR-381-NEFL Axis Sensitizes Glioblastoma Cells to Temozolomide by Regulating Stemness Factors and Multidrug Resistance Factors
Overview
Authors
Affiliations
MicroRNA-381 (miR-381) is a highly expressed onco-miRNA that is involved in malignant progression and has been suggested to be a good target for glioblastoma multiforme (GBM) therapy. In this study, we employed two-dimensional fluorescence differential gel electrophoresis (2-D DIGE) and MALDI-TOF/TOF-MS/MS to identify 27 differentially expressed proteins, including the significantly upregulated neurofilament light polypeptide (NEFL), in glioblastoma cells in which miR-381 expression was inhibited. We identified NEFL as a novel target molecule of miR-381 and a tumor suppressor gene. In human astrocytoma clinical specimens, NEFL was downregulated with increased levels of miR-381 expression. Either suppressing miR-381 or enforcing NEFL expression dramatically sensitized glioblastoma cells to temozolomide (TMZ), a promising chemotherapeutic agent for treating GBMs. The mechanism by which these cells were sensitized to TMZ was investigated by inhibiting various multidrug resistance factors (ABCG2, ABCC3, and ABCC5) and stemness factors (ALDH1, CD44, CKIT, KLF4, Nanog, Nestin, and SOX2). Our results further demonstrated that miR-381 overexpression reversed the viability of U251 cells exhibiting NEFL-mediated TMZ sensitivity. In addition, NEFL-siRNA also reversed the proliferation rate of U251 cells exhibiting locked nucleic acid (LNA)-anti-miR-381-mediated TMZ sensitivity. Overall, the miR-381-NEFL axis is important for TMZ resistance in GBM and may potentially serve as a novel therapeutic target for glioma.
Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma.
Wu H, Gao W, Chen P, Wei Y, Zhao H, Wang F Heliyon. 2024; 10(21):e39984.
PMID: 39568843 PMC: 11577240. DOI: 10.1016/j.heliyon.2024.e39984.
Role of Non-coding RNAs in the Response of Glioblastoma to Temozolomide.
Goleij P, Pourali G, Raisi A, Ravaei F, Golestan S, Abed A Mol Neurobiol. 2024; 62(2):1726-1755.
PMID: 39023794 DOI: 10.1007/s12035-024-04316-z.
Unraveling the noncoding RNA landscape in glioblastoma: from pathogenesis to precision therapeutics.
Sandhanam K, Tamilanban T Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9475-9502.
PMID: 39007929 DOI: 10.1007/s00210-024-03265-7.
Yang Y, Nan Y, Du Y, Huang S, Lu D, Zhang J World J Gastroenterol. 2023; 29(27):4317-4333.
PMID: 37545635 PMC: 10401664. DOI: 10.3748/wjg.v29.i27.4317.
MDK induces temozolomide resistance in glioblastoma by promoting cancer stem-like properties.
Yu X, Zhou Z, Tang S, Zhang K, Peng X, Zhou P Am J Cancer Res. 2022; 12(10):4825-4839.
PMID: 36381313 PMC: 9641408.